--(BUSINESS WIRE)--Highland Therapeutics Inc. is a specialty pharmaceutical company that, through its wholly owned subsidiary Ironshore Pharmaceuticals & Development, Inc., is leveraging its proprietary technology, DELEXIS™, to optimize the delivery of previously approved drug products. The Company's lead product candidates, HLD-200 and HLD-100, are novel formulations of the psychostimulants (methylphenidate and amphetamine, respectively) used to treat ADHD and are being developed to address a prevalent unmet medical need in the treatment of the disease – inadequate symptom control during the morning routine. Intended for nighttime dosing, DELEXIS™ is designed to provide a consistent delay in the initial release of the active drug, followed by a period of extended release; with the objective of providing control of ADHD symptoms immediately upon wakening and throughout the day.
Company: |
Highland Therapeutics Inc. | |
Headquarters Address: |
MaRS Centre, South Tower | |
101 College St., Suite 310 | ||
Toronto, ON M5G 1L7 | ||
Canada | ||
Main Telephone: |
647-260-7875 | |
Website: |
||
Type of Organization: |
Private | |
Industry: |
Pharmaceutical |
|
Key Executives: |
CFO: Nelson Isabel |
|
Investor Relations |
||
Contact: |
Nelson Isabel | |
Phone: |
647-694-1966 x177 | |
Email: |